“Eventually this will spin off into adding a fluorescent tag to it—that’s one of the things we’re working on,” she said. “Then we really won’t have to use a blue dye at all. Perhaps being able to find markers on tumor cells themselves might allow us eventually to be able to tell if a node is positive or negative, and not necessarily have to take the node out.”
Lymphoseek will be distributed exclusively by Cardinal Health starting in the second quarter of 2013. Prescribing Information for Lymphoseek is available online at www.lymphoseek.com.
1. Wallace AM, Han LK, Povoski SP, et al. Comparative evaluation of [99mTc] Tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials. Ann SurgOncol. DOI: 10.1245/s10434-013-2887-8.
2. Tran Cao HS, McElroy M, Kaushal S, et al. Imaging of the interaction of cancer cells and the lymphatic system. Adv Drug Deliv Rev. 2011;63:886-889.
3. Liu T, Cousins A, Chien CC, et al. Immunospecific targeting of CD45 expressing lymphoid cells: towards improved detection agents of the sentinel lymph node. Cancer Letters. 2013;328:271-277.
4. Sondak VK, King DW, Zager JS, et al. Combined analysis of phase III trials evaluating [99m-Tc] Tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann SurgOncol. 2013;20:680-688.